Population pharmacokinetics and exposure-response analysis of sotrovimab in the early treatment of COVID-19
Jennifer E. Sager, Asma El-Zailik, Julie Passarell, Stefan Roepcke, Xiaobin Li, Melissa Aldinger, Ahmed Nader, Andrew Skingsley, Elizabeth L. Alexander, Wendy W. Yeh, Erik Mogalian, Chad Garner, Amanda Peppercorn, View ORCID ProfileAdrienne E. Shapiro, Maribel Reyes
doi: https://doi.org/10.1101/2022.11.23.22282478
Jennifer E. Sager
1Vir Biotechnology, Inc., San Francisco, CA, USA
Asma El-Zailik
1Vir Biotechnology, Inc., San Francisco, CA, USA
Julie Passarell
2Cognigen Division, Simulations Plus, Inc., Buffalo, NY, USA
Stefan Roepcke
2Cognigen Division, Simulations Plus, Inc., Buffalo, NY, USA
Xiaobin Li
3GSK, Upper Providence, PA, USA
Melissa Aldinger
1Vir Biotechnology, Inc., San Francisco, CA, USA
Ahmed Nader
3GSK, Upper Providence, PA, USA
Andrew Skingsley
4GSK, Brentford, UK
Elizabeth L. Alexander
1Vir Biotechnology, Inc., San Francisco, CA, USA
Wendy W. Yeh
1Vir Biotechnology, Inc., San Francisco, CA, USA
Erik Mogalian
1Vir Biotechnology, Inc., San Francisco, CA, USA
Chad Garner
1Vir Biotechnology, Inc., San Francisco, CA, USA
Amanda Peppercorn
5GSK, Cambridge, Massachusetts, USA
Adrienne E. Shapiro
6Fred Hutchinson Cancer Center, Seattle, WA, USA
Maribel Reyes
1Vir Biotechnology, Inc., San Francisco, CA, USA
Data Availability
Individual participant data will not be made publicly available. The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.
Posted November 27, 2022.
Population pharmacokinetics and exposure-response analysis of sotrovimab in the early treatment of COVID-19
Jennifer E. Sager, Asma El-Zailik, Julie Passarell, Stefan Roepcke, Xiaobin Li, Melissa Aldinger, Ahmed Nader, Andrew Skingsley, Elizabeth L. Alexander, Wendy W. Yeh, Erik Mogalian, Chad Garner, Amanda Peppercorn, Adrienne E. Shapiro, Maribel Reyes
medRxiv 2022.11.23.22282478; doi: https://doi.org/10.1101/2022.11.23.22282478
Population pharmacokinetics and exposure-response analysis of sotrovimab in the early treatment of COVID-19
Jennifer E. Sager, Asma El-Zailik, Julie Passarell, Stefan Roepcke, Xiaobin Li, Melissa Aldinger, Ahmed Nader, Andrew Skingsley, Elizabeth L. Alexander, Wendy W. Yeh, Erik Mogalian, Chad Garner, Amanda Peppercorn, Adrienne E. Shapiro, Maribel Reyes
medRxiv 2022.11.23.22282478; doi: https://doi.org/10.1101/2022.11.23.22282478
Subject Area
Subject Areas
- Addiction Medicine (373)
- Allergy and Immunology (690)
- Anesthesia (184)
- Cardiovascular Medicine (2760)
- Dermatology (236)
- Emergency Medicine (414)
- Epidemiology (12413)
- Forensic Medicine (10)
- Gastroenterology (784)
- Genetic and Genomic Medicine (4272)
- Geriatric Medicine (396)
- Health Economics (702)
- Health Informatics (2761)
- Health Policy (1021)
- Hematology (370)
- HIV/AIDS (880)
- Medical Education (404)
- Medical Ethics (112)
- Nephrology (454)
- Neurology (4054)
- Nursing (218)
- Nutrition (600)
- Oncology (2134)
- Ophthalmology (607)
- Orthopedics (251)
- Otolaryngology (313)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (479)
- Pediatrics (1150)
- Primary Care Research (470)
- Public and Global Health (6663)
- Radiology and Imaging (1453)
- Respiratory Medicine (886)
- Rheumatology (422)
- Sports Medicine (353)
- Surgery (465)
- Toxicology (57)
- Transplantation (192)
- Urology (171)